Page last updated: 2024-12-05
diethylene glycol dimethacrylate monomer
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 16891 |
| CHEMBL ID | 3186638 |
| SCHEMBL ID | 24260 |
| MeSH ID | M0137210 |
Synonyms (61)
| Synonym |
|---|
| di(ethylene glycol) dimethacrylate, 95% |
| diethylene glycol bis(methacrylate) |
| tgm 2 |
| methacrylic acid, oxydiethylene ester |
| dgm 2 |
| oxydiethylene methacrylate |
| diethylene glycol dimethacrylate monomer |
| diethylene glycol dimethacrylate |
| oxydi-2,1-ethanediyl bismethacrylate |
| diethyleneglycol dimethacrylate |
| 2-propenoic acid, 2-methyl-, oxydi-2,1-ethanediyl ester |
| einecs 219-099-9 |
| hsdb 5458 |
| ccris 7050 |
| 2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethyl 2-methylprop-2-enoate |
| D1530 |
| 2358-84-1 |
| 2-propenoic acid, 2-methyl-, 1,1'-(oxydi-2,1-ethanediyl) ester |
| unii-r42pui926f |
| r42pui926f , |
| tox21_301734 |
| dtxsid8044882 , |
| NCGC00256100-01 |
| di(ethylene glycol) dimethacrylate |
| cas-2358-84-1 |
| dtxcid6024882 |
| 25101-18-2 |
| FT-0624887 |
| AKOS015903120 |
| diethylene glycol dimethacrylate [inci] |
| diethylene glycol bis(methacrylate) [hsdb] |
| methacrylic acid, diester with diethylene glycol |
| diethylene glycol, dimethacrylate |
| 2,2'-oxybisethanol dimethacrylate |
| 2,2'-oxydiethyl dimethacrylate |
| light ester 2eg |
| blemmer pde 100 |
| SCHEMBL24260 |
| diethyleneglycoldimethacrylate |
| XFCMNSHQOZQILR-UHFFFAOYSA-N |
| mfm-418 |
| ageflex degdma |
| 3-oxapentane-1,5-diyl dimethacrylate |
| 2-[2-(methacryloyloxy)ethoxy]ethyl 2-methylacrylate # |
| CHEMBL3186638 |
| diethylene glycol dimethacrylate(8 cp(20 degrees c)) |
| mfcd00014931 |
| diethylene glycol dimethacrylate, (stabilized with mehq) |
| di(ethylene glycol) dimethacrylate, 96% |
| diethylene glycol dimethacrylate (stabilized with mehq) |
| J-015158 |
| 2,2'-oxybis(ethane-2,1-diyl) bis(2-methylacrylate) |
| 129011-76-3 |
| Q27287772 |
| oxybis(ethane-2,1-diyl) bis(2-methylacrylate) |
| BS-48957 |
| oxybis(ethane-2,1-diyl)bis(2-methylacrylate) |
| 2-{2-[(2-methylprop-2-enoyl)oxy]ethoxy}ethyl 2-methylprop-2-enoate |
| CS-W010276 |
| E82986 |
| 2-methyl-2-propenoic acid oxidi-2,1-ethanediyl ester,homopolymer |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (4)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 61.6448 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743078 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 61.6448 | 0.0237 | 23.2282 | 63.5986 | AID743222 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 61.6448 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 54.4827 | 0.0006 | 27.2152 | 1,122.0200 | AID743202 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.12
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.12) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||